Edesa Biotech Inc
NASDAQ:EDSA
Intrinsic Value
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medica... [ Read More ]
The intrinsic value of one EDSA stock under the Base Case scenario is 1.327 USD. Compared to the current market price of 4.465 USD, Edesa Biotech Inc is Overvalued by 70%.
Valuation Backtest
Edesa Biotech Inc
Run backtest to discover the historical profit from buying and selling EDSA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Edesa Biotech Inc
Current Assets | 5.4m |
Cash & Short-Term Investments | 4.3m |
Receivables | 743.6k |
Other Current Assets | 404.9k |
Non-Current Assets | 2.4m |
PP&E | 83.1k |
Intangibles | 2.2m |
Other Non-Current Assets | 177.7k |
Current Liabilities | 2m |
Accounts Payable | 1.9m |
Accrued Liabilities | 78.3k |
Earnings Waterfall
Edesa Biotech Inc
Revenue
|
0
USD
|
Operating Expenses
|
-8.7m
USD
|
Operating Income
|
-8.7m
USD
|
Other Expenses
|
988.3k
USD
|
Net Income
|
-7.7m
USD
|
Free Cash Flow Analysis
Edesa Biotech Inc
EDSA Profitability Score
Profitability Due Diligence
Edesa Biotech Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Edesa Biotech Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
EDSA Solvency Score
Solvency Due Diligence
Edesa Biotech Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Edesa Biotech Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EDSA Price Targets Summary
Edesa Biotech Inc
According to Wall Street analysts, the average 1-year price target for EDSA is 24.48 USD with a low forecast of 19.19 USD and a high forecast of 33.6 USD.
Ownership
EDSA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
EDSA Price
Edesa Biotech Inc
Average Annual Return | -14.56% |
Standard Deviation of Annual Returns | 46.13% |
Max Drawdown | -97% |
Market Capitalization | 14.1m USD |
Shares Outstanding | 3 215 970 |
Percentage of Shares Shorted | 0.75% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. The firm is focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune related diseases with clear unmet medical needs. The company is organized under the laws of British Columbia, Canada. The Company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, which the Company is developing as a treatment for acute respiratory distress syndrome (ARDS) in COVID19 patients. ARDS is a life-threatening form of respiratory failure and the leading cause of death among COVID19 patients. ARDS can be also caused by bacterial pneumonia, sepsis, chest injury and other causes. The company is developing a secreted phospholipases A2 (sPLA2) inhibitor, designated as EB01, as a treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. EB01 employs a nonsteroidal mechanism of action.
Contact
IPO
Employees
Officers
The intrinsic value of one EDSA stock under the Base Case scenario is 1.327 USD.
Compared to the current market price of 4.465 USD, Edesa Biotech Inc is Overvalued by 70%.